GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Equity-to-Asset

Keymed Biosciences (HKSE:02162) Equity-to-Asset : 0.77 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Keymed Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$3,266.4 Mil. Keymed Biosciences's Total Assets for the quarter that ended in Dec. 2023 was HK$4,247.1 Mil. Therefore, Keymed Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.77.

The historical rank and industry rank for Keymed Biosciences's Equity-to-Asset or its related term are showing as below:

HKSE:02162' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.07   Med: 0.77   Max: 0.93
Current: 0.77

During the past 5 years, the highest Equity to Asset Ratio of Keymed Biosciences was 0.93. The lowest was -2.07. And the median was 0.77.

HKSE:02162's Equity-to-Asset is ranked better than
63.32% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:02162: 0.77

Keymed Biosciences Equity-to-Asset Historical Data

The historical data trend for Keymed Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Equity-to-Asset Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-0.42 -2.07 0.93 0.85 0.77

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only 0.93 0.89 0.85 0.83 0.77

Competitive Comparison of Keymed Biosciences's Equity-to-Asset

For the Biotechnology subindustry, Keymed Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keymed Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Keymed Biosciences's Equity-to-Asset falls into.



Keymed Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Keymed Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3266.364/4247.058
=0.77

Keymed Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3266.364/4247.058
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Keymed Biosciences  (HKSE:02162) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Keymed Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Keymed Biosciences (HKSE:02162) Business Description

Traded in Other Exchanges
Address
No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.

Keymed Biosciences (HKSE:02162) Headlines

No Headlines